• About
  • Advertise
  • Privacy & Policy
  • Contact
HK Businesswire
  • Home
  • News
    • All
    • Business
    • Politics
    • PR Newswire
    • Science
    • World

    EC election ‘open, honest and fair’, says David Lok

    Chongqing International Talent Exchange Conference Opens, Drawing Nobel Laureates and Global Innovators

    Chongqing International Talent Exchange Conference Opens, Drawing Nobel Laureates and Global Innovators

    APEC Business Travel Card is Linking Zhongshan with Asia-Pacific

    APEC Business Travel Card is Linking Zhongshan with Asia-Pacific

    Fossil fuels still missing from latest COP31 draft

    HK-Chile working-holiday scheme to start next year

    HK to contribute to global bay area cooperation: FS

    Trending Tags

    • Trump Inauguration
    • United Stated
    • White House
    • Market Stories
    • Election Results
  • PR Newswire
  • Business
  • World
  • Entertainment
  • Sports
  • Tech
    • All
    • Apps
    • Gadget
    • Mobile
    • Startup

    Cathay Cargo Launches AI Compliance Tool to Streamline Global Trade Operations

    PCCW Global and Druid Technology Partner on Belt and Road IoT Connectivity

    Alipay Launches Domestic Full-Stack Intelligent Agent Platform in Hangzhou

    HKT Posts 4% Profit Rise Amid Steady Local Recovery and AI-Driven Demand

    Alipay Launches AI-Powered Version ‘Abao’ to Streamline Services

    Xiaohongshu Prepares Confidential Hong Kong IPO Filing

    Trending Tags

    • Nintendo Switch
    • CES 2017
    • Playstation 4 Pro
    • Mark Zuckerberg
  • Feature
No Result
View All Result
  • Home
  • News
    • All
    • Business
    • Politics
    • PR Newswire
    • Science
    • World

    EC election ‘open, honest and fair’, says David Lok

    Chongqing International Talent Exchange Conference Opens, Drawing Nobel Laureates and Global Innovators

    Chongqing International Talent Exchange Conference Opens, Drawing Nobel Laureates and Global Innovators

    APEC Business Travel Card is Linking Zhongshan with Asia-Pacific

    APEC Business Travel Card is Linking Zhongshan with Asia-Pacific

    Fossil fuels still missing from latest COP31 draft

    HK-Chile working-holiday scheme to start next year

    HK to contribute to global bay area cooperation: FS

    Trending Tags

    • Trump Inauguration
    • United Stated
    • White House
    • Market Stories
    • Election Results
  • PR Newswire
  • Business
  • World
  • Entertainment
  • Sports
  • Tech
    • All
    • Apps
    • Gadget
    • Mobile
    • Startup

    Cathay Cargo Launches AI Compliance Tool to Streamline Global Trade Operations

    PCCW Global and Druid Technology Partner on Belt and Road IoT Connectivity

    Alipay Launches Domestic Full-Stack Intelligent Agent Platform in Hangzhou

    HKT Posts 4% Profit Rise Amid Steady Local Recovery and AI-Driven Demand

    Alipay Launches AI-Powered Version ‘Abao’ to Streamline Services

    Xiaohongshu Prepares Confidential Hong Kong IPO Filing

    Trending Tags

    • Nintendo Switch
    • CES 2017
    • Playstation 4 Pro
    • Mark Zuckerberg
  • Feature
No Result
View All Result
HK Businesswire
No Result
View All Result
Home News PR Newswire

Harbour BioMed’s Partner Spruce Biosciences Separates CRHX-101 Program into Adrenyx Biosciences, Advancing Development of Harbour BioMed-Originated Antibody through a Standalone Company

PR Newswire by PR Newswire
18 November 2026
in PR Newswire
0
First Patients Dosed in Phase 2 SIRIUS COPD Study of HBM9378/WIN378, a Fully Human Ultra Long-Acting Anti-TSLP Antibody
0
SHARES
2
VIEWS
Share on FacebookShare on Twitter

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Nov. 18, 2026 /PRNewswire/ — Harbour BioMed (the “Company”; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology, oncology and other areas, today announced that its partner Spruce Biosciences (Nasdaq: SPRB) (“Spruce”) has separated its CRHX-101 (formerly SPR-202 and HBM9013) program into Adrenyx Biosciences (“Adrenyx”).

Adrenyx is a newly established, wholly-owned subsidiary of Spruce focused on endocrinology. This company is expected to be listed on Nasdaq in the first half of 2027. Upon completion of the planned pro rata distribution of Adrenyx common stock to Spruce shareholders, Harbour BioMed expects to hold equity interests in both Spruce and Adrenyx.

CRHX-101 is a monoclonal antibody designed to selectively neutralize corticotropin-releasing hormone (CRH), an upstream driver of adrenal androgen excess in classic congenital adrenal hyperplasia (CAH). By targeting CRH at the top of the hormonal signaling cascade, CRHX-101 is being developed with the potential to achieve durable upstream disease control and reduce patients’ reliance on chronic high-dose glucocorticoid therapy, a longstanding challenge in CAH management. Adrenyx’s near-term priorities include completion of IND-enabling nonclinical and chemistry, manufacturing and controls activities, the filing of an Investigational New Drug application for CRHX-101 with the U.S. Food and Drug Administration (the “FDA”), and initiation of a clinical program thereafter.

To support the development of CRHX-101, Adrenyx has secured an initial US$5 million under a secured convertible note purchase arrangement, with the potential to issue up to US$10 million in aggregate principal amount. In addition, a private placement of Adrenyx equity securities to institutional investors is expected to be completed in connection with the planned distribution, with up to US$50 million funded by the convertible notes investor, inclusive of the notes funding.

Dr. Jingsong Wang, Founder, Chairman and CEO of Harbour BioMed, commented: “We are pleased to see the continued advancement of CRHX-101 through a dedicated corporate structure. The establishment of Adrenyx reflects a focused approach to advancing CRHX-101 and supporting its next stage of development. We look forward to the continued progress of CRHX-101 in addressing the significant unmet medical needs of people living with CAH.”

CRHX-101 originated from HBM Alpha Therapeutics (HBMAT), an innovative biotechnology company incubated by Harbour BioMed. In January 2025, HBMAT entered into a collaboration and license agreement with Spruce, granting Spruce exclusive rights to develop and commercialize this molecule outside Greater China (including mainland China, Hong Kong, Macau and Taiwan). Under the agreement, HBMAT is eligible to receive up to US$395 million, including upfront, development, regulatory and commercial milestone payments, as well as tiered royalties on future net product sales. Additionally, HBMAT was granted a warrant to receive minority interest in the partner. In January 2026, Harbour BioMed announced that its wholly-owned subsidiary had exercised the warrants.

About Harbour BioMed

Harbour BioMed (HKEX: 02142) is a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology, oncology and other areas. The Company is building a robust portfolio and differentiated pipeline through internal R&D capability, strategic global collaborations in co-discovery and co-development, and selective acquisitions.

Our proprietary antibody technology platform, Harbour Mice®, generates fully human monoclonal antibodies in both the conventional two heavy and two light chain (H2L2) format and the heavy chain-only (HCAb) format. Building upon HCAb antibodies, the HCAb-based immune cell engagers (HBICE®) bispecific antibody technology enables tumor-killing effects that traditional combination therapies cannot achieve. The HCAb-based Antibody Plus technology (HCAb PLUS™) provides comprehensive modality solutions for the development of innovative multi-specific medicines in different disease areas. Additionally, building upon the Harbour Mice® platform, Harbour BioMed launched its first fully human Generative AI HCAb Model powered by its Hu-mAtrIx™ AI platform, accelerating the development of innovative therapies.

By integrating Harbour Mice®, HBICE®, HCAb PLUS™, a single B-cell cloning platform and AI technologies, Harbour BioMed has built a highly efficient and distinctive antibody discovery engine for developing next-generation therapeutic antibodies. For more information, please visit www.harbourbiomed.com.

Tags: prnewswire
PR Newswire

PR Newswire

PR Newswire is the industry’s leading press release distribution partner with an unparalleled global reach of more than 440,000 newsrooms, websites, direct feeds, journalists and influencers and is available in more than 170 countries and 40 languages. From our award-winning Content Services offerings, integrated media newsroom and microsite products, Investor Relations suite of services, paid placement and social sharing tools, PR Newswire has a comprehensive catalog of solutions to solve the modern-day challenges PR and communications teams face. For 70 years, PR Newswire has been the preferred destination for brands to share their most important news stories across the world.

Read More

CARsgen Presents First Clinical Data on Its In Vivo CAR-T Product Candidate CT1182

CARsgen Presents First Clinical Data on Its In Vivo CAR-T Product Candidate CT1182

22 November 2026
DataBeyond Showcases AI Sorting Solutions for Circular Supply Chains at COP31

DataBeyond Showcases AI Sorting Solutions for Circular Supply Chains at COP31

22 November 2026
  • Trending
  • Comments
  • Latest
Newgen reports Revenue of ₹357 crores in Q1 FY’27, up 11% Q1 YoY; Profit After Tax at ₹63 crores, up 26% Q1 YoY

Newgen Software and the Asian Institute of Digital Finance Forge Strategic Partnership to Shape the Future of Enterprise AI

10 November 2026

World Winter Sports Expo 2026 Opens, Charting a New Decade for Ice and Snow and Outdoor Industries

17 October 2026

HK five-year plan offers UK long-term prospects: CE

10 November 2026
Patriot Launches AI Matrix SSD and DRAM Series Engineered for Local AI Workloads

Patriot Launches AI Matrix SSD and DRAM Series Engineered for Local AI Workloads

19 November 2026

EC election ‘open, honest and fair’, says David Lok

22 November 2026
Chongqing International Talent Exchange Conference Opens, Drawing Nobel Laureates and Global Innovators

Chongqing International Talent Exchange Conference Opens, Drawing Nobel Laureates and Global Innovators

22 November 2026
APEC Business Travel Card is Linking Zhongshan with Asia-Pacific

APEC Business Travel Card is Linking Zhongshan with Asia-Pacific

22 November 2026

Fossil fuels still missing from latest COP31 draft

22 November 2026

Recent News

EC election ‘open, honest and fair’, says David Lok

22 November 2026
Chongqing International Talent Exchange Conference Opens, Drawing Nobel Laureates and Global Innovators

Chongqing International Talent Exchange Conference Opens, Drawing Nobel Laureates and Global Innovators

22 November 2026
APEC Business Travel Card is Linking Zhongshan with Asia-Pacific

APEC Business Travel Card is Linking Zhongshan with Asia-Pacific

22 November 2026

Fossil fuels still missing from latest COP31 draft

22 November 2026
HK Businesswire

Stay ahead with the latest insights on Hong Kong’s economy, finance, and investments. From market trends to policy updates, we bring you in-depth analysis and expert opinions.

📩 Subscribe to our newsletter for exclusive updates.
📍 Follow us on social media for real-time news.
📧 Contact us: info@hongkong-invest.com

Follow Us

  • About
  • Advertise
  • Privacy & Policy
  • Contact

© 2025 by HKBusinesswire.com

No Result
View All Result

© 2025 by HKBusinesswire.com